TMO deepened to $464.38 (RSI 24 — extreme oversold). BNTX $88.80 (RSI 33). LLY $985.28 (RSI 43, still below $1,000). MRNA $52.56 (RSI 56, strong-up). CRSP $48.75 (RSI 39, -13.1% 7D). VRTX $485.55 (RSI 54, golden cross). NTLA $12.90 (RSI 49).
Quick Snapshot
| Signal |
Reading |
| Overall |
🔴 LIFE SCIENCES TOOLS COLLAPSING — TMO RSI 24 deepened further from 28, now at $464.38. CRSP -13.1% 7D. BNTX RSI 33 flat. MRNA RSI 56 and VRTX RSI 54 remain the bright spots. LLY $985.28 slightly above yesterday. |
| Key insight |
TMO $464.38 RSI 24 — -7.4% 30D, -19.4% 3M — life sciences tools in free fall. CRSP $48.75 RSI 39, -13.1% 7D — gene editing selling off hard. MRNA $52.56 RSI 56 strong-up golden cross is the one real winner. |
Action Matrix
| Action |
Stocks |
Why |
| 🔍 RESEARCH |
TMO |
$464.38, RSI 24, -7.4% 30D — Thermo Fisher at capitulation |
| ✅ BUY |
BNTX |
$88.80, RSI 33 — mRNA pioneer, still oversold |
| 📈 ACCUMULATE |
LLY |
$985.28, RSI 43, below $1,000 — GLP-1 leader |
| 🔒 HOLD |
MRNA |
$52.56, RSI 56, +19.6% 30D — strong recovery |
| 🔒 HOLD |
VRTX |
$485.55, RSI 54, golden cross — near 52wk high |
| 🔒 HOLD |
NTLA |
$12.90, RSI 49 — near SMA |
| 🔍 WATCH |
CRSP |
$48.75, RSI 39, -13.1% 7D — gene editing selloff |
Data (Validated 2026-03-13)
| Stock |
Price |
7D |
30D |
52wkHi |
RSI |
SMA20 |
vs SMA |
Status |
Action |
| TMO |
$464.38 |
-6.0% |
-7.4% |
-27.9% |
24 |
$506.46 |
-8.3% |
🔴 Extreme oversold |
🔍 Research |
| BNTX |
$88.80 |
-10.7% |
-16.0% |
-32.4% |
33 |
$103.90 |
-14.5% |
🔴 Oversold |
✅ Buy |
| CRSP |
$48.75 |
-13.1% |
-8.3% |
-37.9% |
39 |
$55.37 |
-12.0% |
🟡 Dropping, death cross |
🔍 Watch |
| LLY |
$985.28 |
+0.1% |
-4.9% |
-13.1% |
43 |
$1,015.39 |
-3.0% |
🟡 Below SMA, below $1K |
📈 Accumulate |
| NTLA |
$12.90 |
-5.4% |
+11.0% |
-54.0% |
49 |
$13.24 |
-2.6% |
🟢 Near SMA |
🔒 Hold |
| VRTX |
$485.55 |
+5.2% |
+4.4% |
-4.0% |
54 |
$478.62 |
+1.4% |
🟢 Golden cross, near high |
🔒 Hold |
| MRNA |
$52.56 |
+3.6% |
+19.6% |
-11.7% |
56 |
$51.46 |
+2.1% |
🟢 Strong-up, golden cross |
🔒 Hold |
Key Changes vs 03/12
| Stock |
03/12 Price |
03/13 Price |
Move |
Note |
| TMO |
$476.70 |
$464.38 |
-2.6% |
RSI 28 → 24 — deepening into extreme oversold |
| CRSP |
$48.87 |
$48.75 |
-0.2% |
-13.1% 7D continuing — RSI 39 |
| LLY |
$976.59 |
$985.28 |
+0.9% |
Slight bounce — RSI 41 → 43 |
| MRNA |
$54.51 |
$52.56 |
-3.6% |
Pullback — RSI 60 → 56, still strong-up |
Key Discoveries
| Discovery |
Implication |
| TMO RSI 24 deepening from 28 |
Life sciences tools sector in freefall — Thermo Fisher at multi-year oversold |
| CRSP -13.1% 7D |
Gene editing under acute selling pressure |
| MRNA pullback RSI 60→56 but still strong-up |
mRNA recovery thesis intact despite giveback |
Open Questions
- TMO RSI 24 — capitulation entry or more downside?
- CRSP -13.1% 7D — catalyst or sector rotation?
- LLY below $1,000 — does $950 hold?